---
title: ABCA2 GIRMS Analytical Validation Clinical Performance Study
nct_id: NCT04607304
overall_status: COMPLETED
phase: NA
sponsor: Cairn Diagnostics
study_type: INTERVENTIONAL
primary_condition: Gastroparesis
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04607304.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04607304"
ct_last_update_post_date: 2021-07-30
last_seen_at: "2026-05-12T07:28:38.584Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# ABCA2 GIRMS Analytical Validation Clinical Performance Study

**Official Title:** ABCA2 GIRMS Analytical Validation Clinical Performance Study - Patient Sample Collection

**NCT ID:** [NCT04607304](https://clinicaltrials.gov/study/NCT04607304)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 95
- **Lead Sponsor:** Cairn Diagnostics
- **Conditions:** Gastroparesis
- **Start Date:** 2020-10-08
- **Completion Date:** 2021-07-27
- **CT.gov Last Update:** 2021-07-30

## Brief Summary

The purpose of this study is to collect human breath samples for use in a validation study intended to demonstrate equivalent clinical performance measures of new ABCA2 GIRMS (Automated Breath Carbon Analyzer-2 Gas Isotope Ratio Mass Spectrometer) instruments to the currently FDA-approved ABCA GIRMS (Automated Breath Carbon Analyzer Gas Isotope Ratio Mass Spectrometer) system. ABCA GIRMS systems are used to analyze the ratio of 13CO2 to 12CO2 in patient breath samples during the GEBT (Gastric Emptying Breath Test) procedure.

## Detailed Description

In this study the participants will be administered the FDA-approved GEBT test, which involves collecting breath samples prior to and after consumption of a non-radioactive carbon stable isotope (13C) labeled test meal. Breath samples will be collected at times consistent with FDA approved labeling. Participant's breath samples will be analyzed on the currently approved ABCA GIRMS and on the new ABCA2 GIRMS instruments. The values collected from both systems will be used to determine the clinical diagnostic agreement at each individual time points and percent agreement in diagnosis between the approved ABCA GIRMS and the new ABCA2 GIRMS.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 85 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Males and females, 18-85 old at time of signing the informed consent form fro healthy and intended use population participants (i.e. symptomology of gastroparesis). Women of childbearing potential must not be pregnant at the time of GEBT administration.
* Ability to eat test meal and provide breath samples

Exclusion Criteria:

* History or physical exam suggestive of pathophysiologic disorders such as renal failure, chronic heart disease, chronic respiratory disease, liver disease or malabsorption syndrome
* History of abdominal surgery except appendectomy
* Use of any medications that may alter gastric motility within two days of the study
* Use of narcotics or anticholinergics within two days of the study
* Females on hormone replacement therapy other than birth control medications
* Receipt of an investigational drug within 4 weeks of the study
* Pregnancy
* Intolerance or allergy to any component of Gastric Emptying Breath Test meal
* History of neurologic or psychiatric disorders
```

## Arms

- **ABCA2 GIRMS** (EXPERIMENTAL) — Leftover breath samples analyzed on ABCA2 GIRMS systems, order of analysis randomized

## Interventions

- **ABCA2 GIRMS** (DEVICE) — Two systems (ABCA-C and ABCA-D) with run order randomized

## Primary Outcomes

- **Diagnostic agreement at each individual timepoints** _(time frame: Up to 7 days per participant)_ — Gastric emptying rates (kPCD) values compared between the validated ABCA GIRMS system and the new ABCA2 GIRMS systems for each GEBT post meal collection timepoint (45, 90, 120, 150, 180 and 240-minute timepoints) and the overall diagnosis
- **Percent agreement in diagnosis** _(time frame: Up to 7 days per participant)_ — Diagnosis compared between the comparative method (ABCA GIRMS) and the candidate method (ABCA2 GIRMS) at each post meal timepoint and the overall diagnosis

## Locations (1)

- Cairn Diagnostics, Brentwood, Tennessee, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.cairn diagnostics|brentwood|tennessee|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04607304.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04607304*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*